Navigation Links
BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
Date:7/16/2013

n> and Turkey, and 22 Middle Eastern & North African countries. Since 2011, XIAPEX has been approved for the treatment of Dupuytren's contracture in 28 EU member countries, Switzerland, and Norway. Sobi, via its Partner Products business unit, will be primarily responsible for the applicable regulatory, clinical and commercialization activities for XIAPEX in Dupuytren's contracture and Peyronie's disease in these countries.

BioSpecifics will receive a certain percentage of milestone payments that Sobi pays to Auxilium.  BioSpecifics will also receive royalties from net sales and payments on costs of goods sold in Sobi territories from Auxilium, which will be a specified percentage of what Auxilium receives from Sobi. 

Sobi is an international specialty healthcare company dedicated to rare diseases with three late stage biological development projects.  In 2012, Sobi had over $250 million in total revenues and about 500 employees.  Sobi shares are traded on the NASDAQ OMX Stockholm exchange.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. CCH is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration has accepted for filing Auxilium's supplemental Biologics License Application for XIAFLEX for the potential treatment of Peyronie's disease. The FDA is expected to take action o
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
5. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
6. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
8. UV Flu Technologies Expands Its International Footprint
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
10. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
11. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 ... en 1974, a été depuis 40 ... les évaluations cliniques traditionnelles par des évaluations ... et sur les impacts économiques des traitements. ... A cours d,une récente ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
(Date:9/18/2014)... everything we touch in the course of a ... even medicines, rely on the chemical industry to ... and farm products into valuable chemicals that are ... scientist Dr Sarina Sarina, who achieved outstanding progress ... at ambient temperature using light instead of fossil ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fête ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Using solar energy to turn raw materials into ingredients for every day life 2
... Sangart, Inc., a privately held biopharmaceutical company focused ... today announced the receipt of approximately $50 million in ... the exercise of warrants issued by Sangart as part ... The most recent investment brings the total funding ...
... WEST CONSHOHOCKEN, Pa., March 12 GEL Interactive ... today it will launch the most recent version of ... NV, March 23-25. GEL will be located in Booth ... its comprehensive event intelligence platform.GEL,s Immerse platform enables customers ...
... Inc. (TSX:SDI) today announced its operational highlights and financial ... , "In 2008, we accomplished several key objectives on ... sepsis for the U.S. market," said Dr. Paul Walker, ... to key terms with Toray Industries, Inc. (Toray) of ...
Cached Biology Technology:Sangart, Inc. Completes Series F Funding Round 2Cadient Group's GEL Interactive Technologies to Launch Immerse(SM) Exhibit 4.0 at EXHIBITOR2009 2Spectral announces 2008 financial results 2Spectral announces 2008 financial results 3Spectral announces 2008 financial results 4Spectral announces 2008 financial results 5Spectral announces 2008 financial results 6Spectral announces 2008 financial results 7Spectral announces 2008 financial results 8
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... plastic shopping bags and their environmental impact recently scored ... first statewide ban on the bags, and Governor Jerry ... bag industry is not yielding without a fight, according ... , the weekly newsmagazine of the American Chemical Society. ... that the anti-bag campaign logged its first small victory ...
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Iberian pig genome remains unchanged after 5 centuries 2
... -- Scientists from The Forsyth Institute and Kings College, ... community, the Human Oral Microbiome Database, which provides descriptions ... commonly found in peoples mouths. Most bacteria living ... maintaining the health of teeth and gums, as well ...
... a biosensing nanodevice developed by Arizona State University ... airport security checkpoints and revolutionize health screenings for ... aureus (MRSA). Even more incredible than the ... the worlds tiniest rotary motor: a biological engine ...
... ... covert data -, LAKE WORTH, Fla., March 24 ... produce the,world,s first self-authenticating passport. It was introduced in the new,Belgian passport ... produces the Belgian passport,has added an optical decoder page in the passport ...
Cached Biology News:Scientists launch human oral microbiome database 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3FCO and GSSC Team to Create World's First Self-Authenticating Passport 2